Author
|
Year
|
Cohort size
|
Mean age, y (range)
|
Female sex, %
|
Rx Dose duration
|
Severity, %
|
Duration, d
|
Follow-up, mo
|
Completion rate, %
|
Blind
|
Class
|
NH, %
|
RR good recovery (CI)
|
RR complete recovery (CI)
|
| Adour19 |
1996 |
99 |
43 |
51 |
400 mg x 5 qd, 10 d |
20 |
3 |
12 |
83 |
Yes |
II |
76 |
1.22 (1.02–1.45) |
1.21 (0.98–1.49) |
| De Diego20 |
1998 |
101 |
43 (14–85) |
45 |
800 mg tid,10 d |
1 |
4 |
3 |
89 |
No |
IV |
94 |
0.83 (0.71–0.98) |
— |
Ramos21
|
1992
|
30
|
36
|
—
|
1,000 mg qd,5 d
|
63
|
NS
|
NS
|
100
|
No
|
IV
|
100
|
1.00*
|
—
|
| Completion rate: percentage of subjects followed to study completion; severity: percentage of patients with complete palsy; duration: maximum duration of palsy before starting steroids. |
| * All patients with good recovery. |
| Rx = medication; CI = 95% confidence; NH = natural history, percentage of non–acyclovir-treated patients attaining a good outcome; RR = relative rate of acyclovir-treated patients attaining outcome compared to non–acyclovir-treated patients; NS = not stated. |
|
